Download as pptx, pdf, or txt
Download as pptx, pdf, or txt
You are on page 1of 8

AUTOM Industy

AY E I S H A
CUARESMA
PRODUCT

T H E R E G U L AT I O N O F H O U S E H O L D / U R B A N
Automobile
LINE:
GOVERNMENT
ORGANIZATIONS
AND
A D M I N I S T R AT I V E O R D E R N O . 2 0 1 9 -

CORRESPONDING
0 0 1 9 , “ R E I N S TAT E M E N T O F
REQUIREMENTS OF LICENSING AS
I M P O RT E R S , E X P O RT E R S ,

POLICIES
M A N U FA C T U R E R S , T O L L
M A N U FA C T U R E R S , W H O L E S A L E R S ,
PRODUCT
Automobile
LINE:
SPECIFIC
GUIDELINES OF
HUHS
ESTABLISHMENTS
PRODUCT
Automobile
l. License To Operate (LTO)
• Shall follow the licensing procedure as prescribed.
• Insurance of LTO shall be submitted
• Shall be deemed filed upon payment of required fees and
LINE:
lll. Issuance of Other Authorizations
• Shall comply with the requirements based on existing
FDA rules and regulations

charges. lV. Renewal of Authorizations


• Shall be done within 3 months prior to the validity date
of the LTO.
ll. Certificate of Product Registration (CPR)
• Shall be registered on a per fumalation basis V. Validity of Authoizations
• Having the same base formulation but different colorant • LTO issued to HUHS shall be valid for 3 years. Renewal
shall be registered as variant LTO shall be valid for 5 yrs.
• Shall register the fual or multiple use
PRODUCT
Automobile
LINE:
SPECIFIC REQUIRMENTS FOR
HUHS PRODUCTS
• Poducts that have been banned in the country or manufacture shall not be permitted to enter
Philippine Market.
• Brand names for HUHS products shall not be allowed to contain names that are identical to
those already registered with the FDA in the same product classification.
• Insurance of LTO shall be submitted
PRODUCT

T H E R E G U L AT I O N O F H O U S E H O L D / U R B A N
Automobile
LINE:
ATIC A TESTING
INSPECTION
CERTIFICATION
VEHICLE EMISSIONS ARE TESTED AND APPROVES BY

REQUIREMENTS
T H E P H I L I P P I N E S E N V I R O N M E N TA L M A N A G E M E N T
B U R E A U ( E M B ) ; C E H I C L E S T H AT PA S S T H E T E S T C A N
O B TA I N A C E RT I F I C AT E O F C O M F O R M I T Y F R O M E M B .
T H E D E PA RT M E N T O F L A N D T R A N S P O RT ( D O T ) , W H I C H
O V E R S E E S T H E L A N D T R A N S P O RTAT I O N O F F I C E ( LT O ) ,
PRODUCT
Automobile
l. Application
• Paperwork are prepared by the manufacturer and
examined by ATIC specialist.
• Submit applications to the Philippines BPS.
LINE:
lll. Approval
• BPS will provide the ICC certificate after reviewing all
technical reports, type approval certificates, and
application documents.

ll. Factory Audit and Testing lV. Mass Production


• Draft a test strategy, observe testing in approved labs, • The manufacturer must guarantee that the entire
and submit technical reports to approval to the vehicle or components are constructed in complete
appropriate authorities. conformity with standards, and the yearly maintenance
audit will be undertaken by BPS.
SOURCES:
Affairs, O. O. R. (2023, December 21). Guidances. U.S. Administrator. (n.d.). FDA Circular No. 2020-025 ||
Food And Drug Administration. Implementing Guidelines for Administrative Order No. 2019-
https://www.fda.gov/industry/fda-basics-industry/guidances 0019, “Reinstatement of Requirements of Licensing as Importers,
#:~:text=Guidance%20documents%20describe%20FDA's Exporters, Manufacturers, Toll Manufacturers, Wholesalers,
%20interpretation,and%20testing%20of%20regulated Distributors, Retailers, or Re-Packers of Those Engaged in
%20products. Certain Household/Urban Hazardous Substances, and from the
Requirement of Prior Registration and/or Notification of Said
Philippines vehicle and component certification. (n.d.). Products” - Food and Drug Administration. Food and Drug
https://www.atic-ts.com/philippines-vehicle-and- Administration -. https://www.fda.gov.ph/fda-circular-no-2020-
component-certification/ 025-implementing-guidelines-for-administrative-order-no-2019-
0019-reinstatement-of-requirements-of-licensing-as-importers-
exporters-manufacturers-toll-manufacturers/
https://www.fda.gov.ph/wp-content/uploads/2020/08/FDA-
Circular-No.2020-025.pdf

You might also like